[{"id":"a2a1d2f4-d5fe-44f6-9d4b-6fab3db22983","acronym":"","url":"https://clinicaltrials.gov/study/NCT04783415","created_at":"2021-03-05T13:54:58.401Z","updated_at":"2024-07-02T16:35:28.898Z","phase":"Phase 2","brief_title":"Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma","source_id_and_acronym":"NCT04783415","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD20 • CCND1","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)","tags":["CD20 • CCND1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib) • Ukoniq (umbralisib) • Briumvi (ublituximab-xiiy) • rituximab biosimilar"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/26/2021","start_date":" 03/26/2021","primary_txt":" Primary completion: 07/31/2022","primary_completion_date":" 07/31/2022","study_txt":" Completion: 09/20/2025","study_completion_date":" 09/20/2025","last_update_posted":"2023-11-17"}]